Outpatient Drug Treatment Program Directors' Hepatitis C‐Related Beliefs and Their Relationship to the Provision of HCV Services

Abstract

The hepatitis C virus (HCV) continues to penetrate populations within the United States, especially within the drug‐abusing population. Therefore, drug users need access to HCV testing and medical care, and drug treatment programs are well situated to provide these services. Because directors of these programs are gatekeepers who can influence decisions about service provision, their beliefs about the value of providing particular services for drug treatment program patients are of considerable importance. Directors of 121 outpatient drug treatment programs throughout the United States responded to an in‐depth telephone survey that included questions on their beliefs about providing HCV services in drug treatment programs. We constructed an eight‐item scale to examine these beliefs and investigated the relationship between them and the actual HCV services offered. Overall, directors were moderately supportive of the provision of HCV medical services (on‐site or through referral) during drug treatment. Our findings indicate that there is a positive significant relationship between director's beliefs and the provision of HCV antibody testing, follow‐up testing, and the provision of HCV medication.